These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18642137)

  • 1. Commentary on 'a novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS'.
    Shefner JM; Nigel Leigh P
    Amyotroph Lateral Scler; 2008 Aug; 9(4):254-6. PubMed ID: 18642137
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to commentary on a novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.
    Gordon PH; Cheung YK; Levin B; Andrews H; Mitsumoto H
    Amyotroph Lateral Scler; 2009 Feb; 10(1):author reply 61. PubMed ID: 18985463
    [No Abstract]   [Full Text] [Related]  

  • 3. Selecting promising ALS therapies in clinical trials.
    Cheung YK; Gordon PH; Levin B
    Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
    IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)].
    Yanagisawa N; Shindo M
    Rinsho Shinkeigaku; 1996 Dec; 36(12):1329-30. PubMed ID: 9128396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial.
    Levin BJ; Thompson G; Mitsumoto LH; Kaufmann P
    Neurology; 2006 Jun; 66(11):1786-7; author reply 1786-7. PubMed ID: 16769973
    [No Abstract]   [Full Text] [Related]  

  • 7. Rilutek (Riluzole) may extend survival in amyotrophic lateral sclerosis.
    J Neurosci Nurs; 1996 Aug; 28(4):275. PubMed ID: 8880606
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic trials in ALS.
    Bradley W
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Apr; 4(1):6-7. PubMed ID: 12745610
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuroprotective agents for clinical trials in ALS: systematic assessment.
    Burke WJ
    Neurology; 2007 Feb; 68(9):709; author reply 710. PubMed ID: 17325287
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug therapy in amyotrophic lateral sclerosis.
    Distad BJ; Meekins GD; Liou LL; Weiss MD; Carter GT; Miller RG
    Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):633-51, xi-xii. PubMed ID: 18625421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold.
    Armon C; Guiloff RJ; Bedlack R
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Sep; 3(3):109-12. PubMed ID: 12495570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALSUntangled No. 8: Low dose naltrexone for ALS.
    ALSUntangled Group
    Amyotroph Lateral Scler; 2011 Jan; 12(1):76-8. PubMed ID: 21174518
    [No Abstract]   [Full Text] [Related]  

  • 13. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
    Gordon PH
    Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC; Drory VE
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuroprotective agents for clinical trials in ALS: a systematic assessment.
    Traynor BJ; Bruijn L; Conwit R; Beal F; O'Neill G; Fagan SC; Cudkowicz ME
    Neurology; 2006 Jul; 67(1):20-7. PubMed ID: 16832072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy development for ALS: lessons learned and path forward.
    Lanka V; Cudkowicz M
    Amyotroph Lateral Scler; 2008 Jun; 9(3):131-40. PubMed ID: 18574756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development of levetiracetam for amyotrophic lateral sclerosis.
    Davies SL; Moral MA
    Drug News Perspect; 2006 Nov; 19(9):572-3. PubMed ID: 17220961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS.
    Gordon PH; Cheung YK; Levin B; Andrews H; Doorish C; Macarthur RB; Montes J; Bednarz K; Florence J; Rowin J; Boylan K; Mozaffar T; Tandan R; Mitsumoto H; Kelvin EA; Chapin J; Bedlack R; Rivner M; McCluskey LF; Pestronk A; Graves M; Sorenson EJ; Barohn RJ; Belsh JM; Lou JS; Levine T; Saperstein D; Miller RG; Scelsa SN;
    Amyotroph Lateral Scler; 2008 Aug; 9(4):212-22. PubMed ID: 18608093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Etiological drug therapy for amyotrophic lateral sclerosis].
    Cintas P
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S220-4S227. PubMed ID: 17128115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selecting promising ALS therapies in clinical trials.
    Glass JD; Benatar M; Polak M
    Neurology; 2007 May; 68(18):1545-6; author reply 1546. PubMed ID: 17470765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.